Chronic Myeloid Leukemia (CML) requires vigilant long-term monitoring to track disease progression and detect resistance to tyrosine kinase inhibitors (TKIs). While traditional clinical assays are effective, they are often expensive and mechanism-specific. However, a new study evaluates Raman spectroscopy for CML as a mechanism-independent diagnostic tool. This method captures a comprehensive macromolecular profile from patient samples, providing a "chemical fingerprint" of the malignancy.

The research team analyzed blood-derived cells, plasma, and serum from 32 CML patients and 12 healthy controls. They utilized advanced computational techniques like Principal Component Analysis combined with Linear Discriminant Analysis (PC-LDA). Consequently, they identified distinct biochemical variations in protein and fatty acid signatures between CML and control groups. Specifically, these signatures help differentiate leukemic states based on unique molecular vibrations.

Clinical Advantages of Raman Spectroscopy for CML

The PC-LDA model achieved significant classification accuracies across different biological materials. Serum samples yielded an accuracy of 88.64%, while plasma achieved 86.36%. Furthermore, when researchers fused data from all sample types, the diagnostic accuracy surged to between 95.12% and 100%. Therefore, data fusion significantly enhances the reliability of this spectroscopic approach. Moreover, Multivariate Curve Resolution (MCR) successfully identified discriminative spectral components in both plasma and serum.

Additionally, the study concludes that serum is currently the most suitable material for future clinical diagnostics. This platform could eventually offer a cost-effective, real-time monitoring solution for CML patients. Finally, these findings establish a strong methodological foundation for developing mechanism-independent monitoring platforms. Such tools are vital for detecting TKI resistance, especially when underlying mechanisms remain poorly understood.

Frequently Asked Questions

How accurate is Raman spectroscopy for CML detection?

The study found that Raman spectroscopy achieves high accuracy, particularly when using serum (88.64%). When researchers combine data from cells, plasma, and serum, the diagnostic accuracy reaches between 95% and 100%.

Why is serum preferred over plasma or cells in this method?

Serum provides a more stable and distinct biochemical profile of proteins and fatty acids. This stability makes it the most effective material for identifying the unique molecular vibrations associated with CML progression.

Can this method replace existing TKI resistance tests?

While it is not yet a replacement, it offers a mechanism-independent alternative. This is particularly useful for detecting resistance in the terminal phases of CML where current mechanism-specific tests may fail to capture the full disease profile.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Refer to the latest local and national guidelines for clinical practice.

References

Nath S et al. Comparison of biological materials to assess their suitability for Raman spectroscopic detection of chronic myeloid leukemia. Anal Methods. 2026 Feb 10. doi: 10.1039/d5ay01729g. PMID: 41664976.

Silva AM et al. Spectral model for diagnosis of acute leukemias in whole blood and plasma through Raman spectroscopy. J Biomed Opt. 2018 Oct;23(10):1-10.

Managò S et al. Raman microscopy based sensing of leukemia cells: a review. Opt Laser Technol. 2018;108:7-16.